Stratos Wealth Partners’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
Other funds holding PHAT
Stratos Wealth Partners's PHAT Position: Q3 2026 in Review
Stratos Wealth Partners sold out of Phathom Pharmaceuticals (PHAT) in Q3 2026, closing a stake of 100,000 shares — an estimated $1.08M sold.
Stratos Wealth Partners first reported a position in PHAT in Q4 2025 and held it in 3 quarters. The position peaked at $1.11M in Q1 2026. 112 funds tracked by Wall St. Rank hold PHAT as of Q3 2026.
- Stratos Wealth Partners reported no remaining Phathom Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- Stratos Wealth Partners sold 100,000 Phathom Pharmaceuticals shares in Q3 2026, an estimated $1.08M.
- Stratos Wealth Partners first reported a position in Phathom Pharmaceuticals in Q4 2025 and held it in 3 quarters.
- Stratos Wealth Partners's Phathom Pharmaceuticals position peaked at $1.11M in Q1 2026.
- 112 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2026.
Based on Stratos Wealth Partners's 13F filing for Q3 2026, filed 13 Nov 2026.